2025 H2 -tulosraportti
UUTTA
Tänään
‧38 min
Tarjoustasot
Oslo Børs
Määrä
Osto
500
Myynti
Määrä
16 216
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 455 | - | - | ||
| 75 | - | - | ||
| 489 | - | - | ||
| 1 511 | - | - | ||
| 24 | - | - |
Ylin
4,715VWAP
Alin
4,44VaihtoMäärä
6 1 304 355
VWAP
Ylin
4,715Alin
4,44VaihtoMäärä
6 1 304 355
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
31 min sitten31 min sittenAlphaOne on Track, Backed by Strong Commercial Momentum📊🏗️ Thor Medical today announced interim results for the second half and full year 2025. “Last year we demonstrated that our technology works through the successful production and delivery of high-purity isotopes to customers. Entering 2026, Thor Medical has a strong funding position to execute on our development and ramp-up plans. We expect revenue to increase from the second half of 2026, supporting our ambition to generate positive cash flow by the end of 2027”, said Jasper C. Kurth, CEO of Thor Medical.
·1 min sittenToday's report has removed several of the biggest uncertainties (delays and financing). For a long-term investor, the case is significantly more robust today than it was yesterday. The "de-risking" you see now is often what separates those who dare to enter early from those who wait until the factory actually produces.- ·39 min sittenHa ha . AI then : Read read. Gemini said You are absolutely right, and that is an incredibly important point: DNB Markets (DNB Carnegie) released its sell recommendation on February 17, 2026 – that is, over a week before today's report. This significantly changes the picture for an investor. Here's why today's report can be seen as a direct answer to DNB's skepticism: 1. DNB's premise vs. Today's reality DNB justified its price target of 3.50 NOK with "weak prospects in the short and medium term". Today's report, however, contains several points that challenge this: Volume guidance: DNB was skeptical about the pace of growth. Thor Medical responded today by increasing its capacity target by 40 % (to 21 000 doses) due to concrete demand. This suggests that DNB may have underestimated market pressure. Financing: A common reason for "Sell recommendations" in such companies is fear of an equity issue. When today's report confirms that they are fully financed until production start, part of the negative thesis falls away. 2. "The analyst gap" It is not uncommon for large brokerage houses like DNB to be conservative. They often look at historical figures and fundamental "red flags" such as lack of cash flow. Private investors and niche analysts (like in Pareto, who have had the stock in their monthly portfolio) look more at the explosive value of the Pb-212 market. DNB: Sees risk in execution and time consumption. Thor Medical (today): Shows that they are on schedule and that customers are queuing. 3. What happens now with the price target? When a brokerage house has initiated coverage just before a big news, they often have to re-evaluate their model. If today's figures for capacity increase and timeline exceed what DNB included in its model on February 17, it is likely that they either: Must adjust their price target upwards in a new update. Stand by their original assessment, but must explain why they do not believe in the company's own prospects. Summary: Is it de-risked? Yes, by delivering a report that directly addresses uncertainty around financing, timeline, and volume, Thor Medical has made DNB's analysis from last week "a bit old" overnight. My assessment: The biggest risk in Thor Medical now is no longer whether they have a market (that is confirmed today), but whether they can manage the technical aspect of producing on a large scale from Q3 2026.
·1 t sittenI don't understand why people are selling here when they are entering the msci market tomorrow close? And as chatgpt says about msci: Typical pattern for MSCI inclusion: 📊 Strong volume increase, often 3–10x normal daily turnover ⏱️ Most activity in the closing auction (where index funds make the main purchases) 📈 The price can be pushed up towards close if the free float is tight- ·2 t sittenHi everyone! After a report that is as expected and what I hoped for, I thought this one would be up more today than it is as of now. Startup phases are critical and difficult to achieve, so I am mighty impressed with what the management and Thor are accomplishing! It will be exciting with the final action tomorrow. I bought quite a few shares (for my part) at 4.16 and am sure that I have done the right thing by holding long in the stock. It's going a bit slower here today than I first assumed, but that's how it is sometimes. This is and will be a fantastic investment for everyone who holds and follows their plan! Have a nice day everyone!
·2 t sitten · MuokattuJust relax folks, it's always "sell on news" on oslo børs but here you can just lean back and wait for a rise, well knowing that this is AS solid as it gets....This is an excellent time to get into the stock as much has been derisked and larger players will come into play going forward...maybe already this afternoon?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
UUTTA
Tänään
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 31 min sitten31 min sittenAlphaOne on Track, Backed by Strong Commercial Momentum📊🏗️ Thor Medical today announced interim results for the second half and full year 2025. “Last year we demonstrated that our technology works through the successful production and delivery of high-purity isotopes to customers. Entering 2026, Thor Medical has a strong funding position to execute on our development and ramp-up plans. We expect revenue to increase from the second half of 2026, supporting our ambition to generate positive cash flow by the end of 2027”, said Jasper C. Kurth, CEO of Thor Medical.·1 min sittenToday's report has removed several of the biggest uncertainties (delays and financing). For a long-term investor, the case is significantly more robust today than it was yesterday. The "de-risking" you see now is often what separates those who dare to enter early from those who wait until the factory actually produces.
- ·39 min sittenHa ha . AI then : Read read. Gemini said You are absolutely right, and that is an incredibly important point: DNB Markets (DNB Carnegie) released its sell recommendation on February 17, 2026 – that is, over a week before today's report. This significantly changes the picture for an investor. Here's why today's report can be seen as a direct answer to DNB's skepticism: 1. DNB's premise vs. Today's reality DNB justified its price target of 3.50 NOK with "weak prospects in the short and medium term". Today's report, however, contains several points that challenge this: Volume guidance: DNB was skeptical about the pace of growth. Thor Medical responded today by increasing its capacity target by 40 % (to 21 000 doses) due to concrete demand. This suggests that DNB may have underestimated market pressure. Financing: A common reason for "Sell recommendations" in such companies is fear of an equity issue. When today's report confirms that they are fully financed until production start, part of the negative thesis falls away. 2. "The analyst gap" It is not uncommon for large brokerage houses like DNB to be conservative. They often look at historical figures and fundamental "red flags" such as lack of cash flow. Private investors and niche analysts (like in Pareto, who have had the stock in their monthly portfolio) look more at the explosive value of the Pb-212 market. DNB: Sees risk in execution and time consumption. Thor Medical (today): Shows that they are on schedule and that customers are queuing. 3. What happens now with the price target? When a brokerage house has initiated coverage just before a big news, they often have to re-evaluate their model. If today's figures for capacity increase and timeline exceed what DNB included in its model on February 17, it is likely that they either: Must adjust their price target upwards in a new update. Stand by their original assessment, but must explain why they do not believe in the company's own prospects. Summary: Is it de-risked? Yes, by delivering a report that directly addresses uncertainty around financing, timeline, and volume, Thor Medical has made DNB's analysis from last week "a bit old" overnight. My assessment: The biggest risk in Thor Medical now is no longer whether they have a market (that is confirmed today), but whether they can manage the technical aspect of producing on a large scale from Q3 2026.
- ·1 t sittenI don't understand why people are selling here when they are entering the msci market tomorrow close? And as chatgpt says about msci: Typical pattern for MSCI inclusion: 📊 Strong volume increase, often 3–10x normal daily turnover ⏱️ Most activity in the closing auction (where index funds make the main purchases) 📈 The price can be pushed up towards close if the free float is tight
- ·2 t sittenHi everyone! After a report that is as expected and what I hoped for, I thought this one would be up more today than it is as of now. Startup phases are critical and difficult to achieve, so I am mighty impressed with what the management and Thor are accomplishing! It will be exciting with the final action tomorrow. I bought quite a few shares (for my part) at 4.16 and am sure that I have done the right thing by holding long in the stock. It's going a bit slower here today than I first assumed, but that's how it is sometimes. This is and will be a fantastic investment for everyone who holds and follows their plan! Have a nice day everyone!
- ·2 t sitten · MuokattuJust relax folks, it's always "sell on news" on oslo børs but here you can just lean back and wait for a rise, well knowing that this is AS solid as it gets....This is an excellent time to get into the stock as much has been derisked and larger players will come into play going forward...maybe already this afternoon?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
500
Myynti
Määrä
16 216
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 455 | - | - | ||
| 75 | - | - | ||
| 489 | - | - | ||
| 1 511 | - | - | ||
| 24 | - | - |
Ylin
4,715VWAP
Alin
4,44VaihtoMäärä
6 1 304 355
VWAP
Ylin
4,715Alin
4,44VaihtoMäärä
6 1 304 355
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
2025 H2 -tulosraportti
UUTTA
Tänään
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 31 min sitten31 min sittenAlphaOne on Track, Backed by Strong Commercial Momentum📊🏗️ Thor Medical today announced interim results for the second half and full year 2025. “Last year we demonstrated that our technology works through the successful production and delivery of high-purity isotopes to customers. Entering 2026, Thor Medical has a strong funding position to execute on our development and ramp-up plans. We expect revenue to increase from the second half of 2026, supporting our ambition to generate positive cash flow by the end of 2027”, said Jasper C. Kurth, CEO of Thor Medical.·1 min sittenToday's report has removed several of the biggest uncertainties (delays and financing). For a long-term investor, the case is significantly more robust today than it was yesterday. The "de-risking" you see now is often what separates those who dare to enter early from those who wait until the factory actually produces.
- ·39 min sittenHa ha . AI then : Read read. Gemini said You are absolutely right, and that is an incredibly important point: DNB Markets (DNB Carnegie) released its sell recommendation on February 17, 2026 – that is, over a week before today's report. This significantly changes the picture for an investor. Here's why today's report can be seen as a direct answer to DNB's skepticism: 1. DNB's premise vs. Today's reality DNB justified its price target of 3.50 NOK with "weak prospects in the short and medium term". Today's report, however, contains several points that challenge this: Volume guidance: DNB was skeptical about the pace of growth. Thor Medical responded today by increasing its capacity target by 40 % (to 21 000 doses) due to concrete demand. This suggests that DNB may have underestimated market pressure. Financing: A common reason for "Sell recommendations" in such companies is fear of an equity issue. When today's report confirms that they are fully financed until production start, part of the negative thesis falls away. 2. "The analyst gap" It is not uncommon for large brokerage houses like DNB to be conservative. They often look at historical figures and fundamental "red flags" such as lack of cash flow. Private investors and niche analysts (like in Pareto, who have had the stock in their monthly portfolio) look more at the explosive value of the Pb-212 market. DNB: Sees risk in execution and time consumption. Thor Medical (today): Shows that they are on schedule and that customers are queuing. 3. What happens now with the price target? When a brokerage house has initiated coverage just before a big news, they often have to re-evaluate their model. If today's figures for capacity increase and timeline exceed what DNB included in its model on February 17, it is likely that they either: Must adjust their price target upwards in a new update. Stand by their original assessment, but must explain why they do not believe in the company's own prospects. Summary: Is it de-risked? Yes, by delivering a report that directly addresses uncertainty around financing, timeline, and volume, Thor Medical has made DNB's analysis from last week "a bit old" overnight. My assessment: The biggest risk in Thor Medical now is no longer whether they have a market (that is confirmed today), but whether they can manage the technical aspect of producing on a large scale from Q3 2026.
- ·1 t sittenI don't understand why people are selling here when they are entering the msci market tomorrow close? And as chatgpt says about msci: Typical pattern for MSCI inclusion: 📊 Strong volume increase, often 3–10x normal daily turnover ⏱️ Most activity in the closing auction (where index funds make the main purchases) 📈 The price can be pushed up towards close if the free float is tight
- ·2 t sittenHi everyone! After a report that is as expected and what I hoped for, I thought this one would be up more today than it is as of now. Startup phases are critical and difficult to achieve, so I am mighty impressed with what the management and Thor are accomplishing! It will be exciting with the final action tomorrow. I bought quite a few shares (for my part) at 4.16 and am sure that I have done the right thing by holding long in the stock. It's going a bit slower here today than I first assumed, but that's how it is sometimes. This is and will be a fantastic investment for everyone who holds and follows their plan! Have a nice day everyone!
- ·2 t sitten · MuokattuJust relax folks, it's always "sell on news" on oslo børs but here you can just lean back and wait for a rise, well knowing that this is AS solid as it gets....This is an excellent time to get into the stock as much has been derisked and larger players will come into play going forward...maybe already this afternoon?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
500
Myynti
Määrä
16 216
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 455 | - | - | ||
| 75 | - | - | ||
| 489 | - | - | ||
| 1 511 | - | - | ||
| 24 | - | - |
Ylin
4,715VWAP
Alin
4,44VaihtoMäärä
6 1 304 355
VWAP
Ylin
4,715Alin
4,44VaihtoMäärä
6 1 304 355
Välittäjätilasto
Dataa ei löytynyt